• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Reply to: "Liver fibrosis and adverse outcomes in COVID-19".回复：“COVID-19中的肝纤维化及不良结局”
Dig Liver Dis. 2021 Jul;53(7):800. doi: 10.1016/j.dld.2021.04.001. Epub 2021 Apr 18.
2
Liver fibrosis and adverse outcomes in COVID-19.COVID-19中的肝纤维化及不良结局
Dig Liver Dis. 2021 Jul;53(7):799. doi: 10.1016/j.dld.2021.03.024. Epub 2021 Apr 1.
3
Reply to: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).回复：2019冠状病毒病（COVID-19）患者肝脏脂肪变性和纤维化与临床结局的关联
Ann Hepatol. 2021 May-Jun;22:100326. doi: 10.1016/j.aohep.2021.100326. Epub 2021 Feb 11.
4
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.CLIF-OF和CCI的联合应用可预测肝硬化合并COVID-19患者的生存率。
Gut. 2021 Sep;70(9):1798-1799. doi: 10.1136/gutjnl-2020-322929. Epub 2020 Oct 7.
5
COVID-19 in patients with cirrhosis: understanding adverse impact.
Gut. 2021 Jul;70(7):1409. doi: 10.1136/gutjnl-2020-322561. Epub 2020 Aug 21.
6
SARS-CoV-2 infection in patients with a normal or abnormal liver.肝脏正常或异常患者的新型冠状病毒2型感染
J Viral Hepat. 2021 Jan;28(1):4-11. doi: 10.1111/jvh.13440. Epub 2020 Dec 1.
7
Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19.肝纤维化指数 FIB-4 升高与 COVID-19 患者的临床预后不良相关。
J Infect Dis. 2020 Aug 4;222(5):726-733. doi: 10.1093/infdis/jiaa355.
8
Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).新型冠状病毒感染（COVID-19）患者中肝脂肪变性和肝纤维化与临床结局的关联
Ann Hepatol. 2021 May-Jun;22:100295. doi: 10.1016/j.aohep.2020.100295. Epub 2020 Nov 27.
9
ACE2: from protection of liver disease to propagation of COVID-19.ACE2：从保护肝脏疾病到传播 COVID-19。
Clin Sci (Lond). 2020 Dec 11;134(23):3137-3158. doi: 10.1042/CS20201268.
10
Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis.失代偿期肝硬化患者中新型冠状病毒2型感染的预防
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):528-529. doi: 10.1016/S2468-1253(20)30080-7. Epub 2020 Mar 17.

引用本文的文献

1
Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19.基于乳酸脱氢酶和转氨酶的指数对合并脂肪肝和 COVID-19 患者的预后评估作用。
World J Gastroenterol. 2022 Oct 7;28(37):5444-5456. doi: 10.3748/wjg.v28.i37.5444.

Reply to: "Liver fibrosis and adverse outcomes in COVID-19".

作者信息

Ruiz-Margáin Astrid, Campos-Murguía Alejandro, González-Regueiro José Alberto, Román-Calleja Berenice Monserrat, Delint Deyanira Kúsulas, Macías-Rodríguez Ricardo Ulises

机构信息

Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Liver Fibrosis and Nutrition lab (LFN-Lab), Mexico City, Mexico; MICTLÁN Network: mechanisms of liver injury, cell death and translational nutrition in liver diseases-research network.

Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

出版信息

Dig Liver Dis. 2021 Jul;53(7):800. doi: 10.1016/j.dld.2021.04.001. Epub 2021 Apr 18.

DOI:10.1016/j.dld.2021.04.001
PMID:33947641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8053236/
Abstract
摘要